Carcinosarcoma
14
3
3
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
2 terminated out of 14 trials
71.4%
-15.1% vs benchmark
0%
0 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
Agnostic Therapy in Rare Solid Tumors
GISAR German Interdisciplinary Sarcoma Registry
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
(VELA) Study of BLU-222 in Advanced Solid Tumors
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma
Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus.
ZW25 in Women With Endometrial Cancers
A Study of Nivolumab in Selected Uterine Cancer Patients
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?
Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors